162 related articles for article (PubMed ID: 17396305)
1. Bevacizumab for non-small-cell lung cancer.
Oxnard GR
N Engl J Med; 2007 Mar; 356(13):1373; author reply 1374-5. PubMed ID: 17396305
[No Abstract] [Full Text] [Related]
2. Bevacizumab for non-small-cell lung cancer.
Garassino MC; Hollander L; Torri V
N Engl J Med; 2007 Mar; 356(13):1373; author reply 1374-5. PubMed ID: 17392310
[No Abstract] [Full Text] [Related]
3. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
Sandler A; Gray R; Perry MC; Brahmer J; Schiller JH; Dowlati A; Lilenbaum R; Johnson DH
N Engl J Med; 2006 Dec; 355(24):2542-50. PubMed ID: 17167137
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab for non-small-cell lung cancer.
Sonpavde G
N Engl J Med; 2007 Mar; 356(13):1374; author reply 1374-5. PubMed ID: 17396304
[No Abstract] [Full Text] [Related]
5. Bevacizumab for non-small-cell lung cancer.
Sculier JP; Meert AP; Paesmans M
N Engl J Med; 2007 Mar; 356(13):1373-4; author reply 1374-5. PubMed ID: 17396306
[No Abstract] [Full Text] [Related]
6. Improved survival with addition of bevacizumab to paclitaxel and carboplatin in elderly patients with non-small-cell lung cancer.
Atkins CD
J Clin Oncol; 2008 Apr; 26(12):2063-4; author reply 2064-5. PubMed ID: 18421066
[No Abstract] [Full Text] [Related]
7. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
8. In focus: non-small cell lung cancer: E1505.
Clin Adv Hematol Oncol; 2007 Mar; 5(3):206-8. PubMed ID: 17519882
[No Abstract] [Full Text] [Related]
9. Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience.
Malhotra B; Evans T; Weiss J; Eaby B; Stonehouse-Lee S; Sherry V; Langer CJ
Clin Lung Cancer; 2010 May; 11(3):192-7. PubMed ID: 20439196
[TBL] [Abstract][Full Text] [Related]
10. Reporting of subset analysis: where do we draw the line?
Goel S
J Clin Oncol; 2008 Apr; 26(12):2062-3; author reply 2064-5. PubMed ID: 18421065
[No Abstract] [Full Text] [Related]
11. Restrictive eligibility limits access to newer therapies in non-small-cell lung cancer: the implications of Eastern Cooperative Oncology Group 4599.
Somer RA; Sherman E; Langer CJ
Clin Lung Cancer; 2008 Mar; 9(2):102-5. PubMed ID: 18501096
[TBL] [Abstract][Full Text] [Related]
12. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599.
Ramalingam SS; Dahlberg SE; Langer CJ; Gray R; Belani CP; Brahmer JR; Sandler AB; Schiller JH; Johnson DH;
J Clin Oncol; 2008 Jan; 26(1):60-5. PubMed ID: 18165641
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect?
Besse B; Le Chevalier T
J Clin Oncol; 2008 Nov; 26(31):5014-7. PubMed ID: 18809602
[No Abstract] [Full Text] [Related]
14. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
Patel JD; Bonomi P; Socinski MA; Govindan R; Hong S; Obasaju C; Pennella EJ; Girvan AC; Guba SC
Clin Lung Cancer; 2009 Jul; 10(4):252-6. PubMed ID: 19632943
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.
Soria JC; Márk Z; Zatloukal P; Szima B; Albert I; Juhász E; Pujol JL; Kozielski J; Baker N; Smethurst D; Hei YJ; Ashkenazi A; Stern H; Amler L; Pan Y; Blackhall F
J Clin Oncol; 2011 Nov; 29(33):4442-51. PubMed ID: 22010015
[TBL] [Abstract][Full Text] [Related]
16. Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histology.
Zinner RG; Saxman SB; Peng G; Monberg MJ; Ortuzar WI
Clin Lung Cancer; 2010 Sep; 11(5):352-7. PubMed ID: 20837462
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.
Langer CJ; Stephenson P; Thor A; Vangel M; Johnson DH;
J Clin Oncol; 2004 Apr; 22(7):1180-7. PubMed ID: 14981103
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab/chemotherapy in non-small-cell lung cancer: looking for a few good men?
Herbst RS
Clin Lung Cancer; 2008 Mar; 9(2):75-6. PubMed ID: 18501092
[No Abstract] [Full Text] [Related]
19. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer.
Goulart B; Ramsey S
Value Health; 2011; 14(6):836-45. PubMed ID: 21914503
[TBL] [Abstract][Full Text] [Related]
20. Anti-angiogenesis drugs in lung cancer.
Lee SM; Baas P; Wakelee H
Respirology; 2010 Apr; 15(3):387-92. PubMed ID: 20337999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
